Wednesday 19 September 2018 ,
Wednesday 19 September 2018 ,
Latest News
  • Govt firmly believes in freedom of press: PM
  • ICC launches Myanmar Rohingya crimes probe
  • Suu Kyi's bronze sculpture to be auctioned for underprivileged in Myanmar
  • North Korea agrees to shut down missile test sites
  • Myanmar domestic commissions fail to report credible atrocities against Rohingya: HRW
10 September, 2018 00:00 00 AM / LAST MODIFIED: 10 September, 2018 01:15:26 AM

FDA approves Xerava

drugs.com
FDA approves Xerava

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently announced that the U.S. Food and Drug Administration (FDA) has granted approval of Xerava (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI). In clinical trials, Xerava was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem.

Xerava is indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Xerava and other antibacterial drugs, Xerava should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

“The approval of Xerava is an extraordinary achievement, one for which we thank the patients who have participated in our clinical studies, study investigators and physicians as well as our dedicated employees,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “We are thrilled to have received FDA approval, and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe all within the same quarter. Each milestone is a significant accomplishment on its own and achieving both underscores the potential for Tetraphase and the medical need for Xerava.”

Dr. Barie added, “Eravacycline also has a favorable safety profile as observed in clinical trials, and no dose adjustment is required when given to patients with renal impairment, which is advantageous for seriously ill patients who may have impaired kidney function. Additionally, the drug may be given safely to patients who are allergic to penicillin. This new and novel treatment may be of great benefit to patients with complicated intra-abdominal infections.”

Intra-abdominal infection (IAI) is a common problem in clinical practice and comprises a wide variety of disease processes. IAI is classified as uncomplicated or complicated based on the extent of the infection. Complicated intra-abdominal infections (cIAI) extend beyond the source organ into the peritoneal space (the space between the two membranes that separate the organs in the abdominal cavity from the abdominal wall) as a result of perforation or other damage to the gastrointestinal tract. cIAI diagnoses include intra-abdominal abscess, stomach or intestinal perforation, peritonitis, appendicitis, cholecystitis, or diverticulitis. Different bacterial pathogens are responsible for cIAI, including Gram-negative aerobic bacteria, Gram-positive bacteria, and anaerobic bacteria.

Early detection, containment and appropriate antimicrobial treatment are essential to the successful treatment of IAI. This is even more critical with increasing rates of infections caused by drug-resistant bacteria, which limit the effectiveness of currently available antibiotics.

Important safety information

Xerava is a tetracycline class antibacterial indicated for the treatment of complicated intra abdominal infections in patients 18 years of age and older.

Xerava is not indicated for the treatment of complicated urinary tract infections.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Xerava and other antibacterial drugs, Xerava should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Xerava is contraindicated for use in patients with known hypersensitivity to eravacycline or to tetracycline-class antibacterial drugs. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with Xerava.

The use of Xerava during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.

The use of Xerava during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.

The most common adverse reactions observed in clinical trials (incidence ≥ 3%) were infusion site reactions, nausea, and vomiting.

Xerava is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri, and anti anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with Xerava. Discontinue Xerava if any of these adverse reactions are suspected.

About Xerava

Xerava (eravacycline for injection) is a novel, fully-synthetic fluorocycline, FDA-approved antibiotic for the treatment of cIAI. Xerava has demonstrated potent activity against MDR pathogens.

Xerava was investigated for the treatment of cIAI as part of the Company's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) phase 3 programs. In the first pivotal phase 3 trial in patients with cIAI, twice-daily intravenous (IV) eravacycline met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated. In the second phase 3 clinical trial in patients with cIAI, twice-daily IV eravacycline met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well-tolerated. In both trials, Xerava achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates.

 

 

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Communication between organs and organ  system is vital. It allows the body to adjust the function of each organ according to the needs of the whole…
What are hormones?

What are hormones?

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to…
Hormones 101 - what you really need to know

Hormones 101 - what you really need to know

While a great number of women in our culture develop some kind of sexual reproductive organ dysfunction, most are misled about true sexual and reproductive…
Hormonal imbalance

Hormonal imbalance

Hormones are your body’s chemical messengers. Produced in the endocrine glands, these powerful chemicals travel around your bloodstream telling…
New hormonal link suspected in type 2 diabetes

New hormonal link suspected in type 2 diabetes

Two disorders that often occur together -- type 2 diabetes and high blood pressure -- may have a common link in a hormone called aldosterone, researchers…
Deadly infections in kids: What you should know about sepsis

Deadly infections in kids: What you should know about sepsis

ITALO M. BROWN If you try on shoes barefoot, can you get a life-threatening infection? It turns out that this may have already happened, according to…
Signs of depression

Signs of depression

While only a qualified medical or mental health provider can diagnose depression, there are certain warning signs that can help you identify whether you…
Lack of exercise puts one in four people at risk, WHO says

Lack of exercise puts one in four people at risk, WHO says

Alex Therrien Very little progress has been made in reducing levels of inactivity worldwide, experts have warned. A WHO report estimates that more than…
Cancers 'rising around the world'

Cancers 'rising around the world'

Smitha Mundasad There will be 18.1 million new cases of cancer and 9.6 million people will die with the disease this year worldwide, a report predicts.…
Folic acid won't curb dangerous pregnancy complication

Folic acid won't curb dangerous pregnancy complication

High doses of folic acid do not protect pregnant women against a sometimes deadly complication called preeclampsia, a large trial suggests. The finding…
 FDA approves Jivi

FDA approves Jivi

Bayer receives FDA approval for Jivi (antihemophilic factor (recombinant), PEGylated-aucl) for prophylactic treatment of hemophilia A Bayer announced…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting